These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 15217925)

  • 61. Bortezomib-induced Sweet syndrome.
    Knoops L; Jacquemain A; Tennstedt D; Theate I; Ferrant A; Van den Neste E
    Br J Haematol; 2005 Oct; 131(2):142. PubMed ID: 16197442
    [No Abstract]   [Full Text] [Related]  

  • 62. New agents and approaches in the treatment of multiple myeloma.
    Anderson KC
    Clin Adv Hematol Oncol; 2003 Mar; 1(3):151-2. PubMed ID: 16224394
    [No Abstract]   [Full Text] [Related]  

  • 63. The role of proteasome in malignant diseases.
    Moran E; Nencioni A
    J BUON; 2007 Sep; 12 Suppl 1():S95-9. PubMed ID: 17935285
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies.
    Caravita T; de Fabritiis P; Palumbo A; Amadori S; Boccadoro M
    Nat Clin Pract Oncol; 2006 Jul; 3(7):374-87. PubMed ID: 16826218
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Severe pulmonary complications after bortezomib treatment for multiple myeloma: an unrecognized pulmonary vasculitis?
    Pitini V; Arrigo C; Altavilla G; Naro C
    Leuk Res; 2007 Jul; 31(7):1027-8. PubMed ID: 17134751
    [No Abstract]   [Full Text] [Related]  

  • 66. A practical update on the use of bortezomib in the management of multiple myeloma.
    San Miguel J; Bladé J; Boccadoro M; Cavenagh J; Glasmacher A; Jagannath S; Lonial S; Orlowski RZ; Sonneveld P; Ludwig H
    Oncologist; 2006 Jan; 11(1):51-61. PubMed ID: 16401713
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Perspective on the current use of bortezomib in multiple myeloma.
    San-Miguel J; Bladé J
    Haematologica; 2006 Jul; 91(7):871-2. PubMed ID: 16818272
    [No Abstract]   [Full Text] [Related]  

  • 68. Anti-angiogenic effect of bortezomib in patients with multiple myeloma.
    Politou M; Naresh K; Terpos E; Crawley D; Lampert I; Apperley JF; Rahemtulla A
    Acta Haematol; 2005; 114(3):170-3. PubMed ID: 16227683
    [No Abstract]   [Full Text] [Related]  

  • 69. Genetic variation associated with bortezomib-induced peripheral neuropathy.
    Favis R; Sun Y; van de Velde H; Broderick E; Levey L; Meyers M; Mulligan G; Harousseau JL; Richardson PG; Ricci DS
    Pharmacogenet Genomics; 2011 Mar; 21(3):121-9. PubMed ID: 21228734
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Bortezomib in multiple myeloma.
    Cecchi M; Caccese E; Messori A
    N Engl J Med; 2005 Sep; 353(12):1297-8; author reply 1297-8. PubMed ID: 16177258
    [No Abstract]   [Full Text] [Related]  

  • 71. Efficacy of bortezomib in systemic extramedullary localizations of multiple myeloma.
    Federico V; Breccia M; Petrucci MT; Loglisci G; Mansueto G; Mercanti C; Levi A; Cartoni C; Musto P; Alimena G
    Clin Adv Hematol Oncol; 2012 Apr; 10(4):266-8. PubMed ID: 22706491
    [No Abstract]   [Full Text] [Related]  

  • 72. Captivating bortezomib: an active but still mysterious drug.
    Di Raimondo F; Conticello C
    Leuk Res; 2010 Apr; 34(4):411-2. PubMed ID: 19819547
    [No Abstract]   [Full Text] [Related]  

  • 73. [The clinical study on treatment with bortezomib for multiple myeloma].
    Chen C; Zhao CL; Hou M
    Zhonghua Xue Ye Xue Za Zhi; 2011 Apr; 32(4):265-7. PubMed ID: 21569711
    [No Abstract]   [Full Text] [Related]  

  • 74. [Development and clinical application of novel proteasome inhibitors].
    Iida S
    Rinsho Ketsueki; 2012 Apr; 53(4):417-25. PubMed ID: 22687975
    [No Abstract]   [Full Text] [Related]  

  • 75. Further progress in the treatment of multiple myeloma?
    Malik PS; Kumar L
    Natl Med J India; 2009; 22(1):25-7. PubMed ID: 19761157
    [No Abstract]   [Full Text] [Related]  

  • 76. [Bortezomib as an alternative in the treatment of patients with malignant gammopathy].
    Lacruz Guzmán D; Funes Vera C; Martínez Penella M; Morales Lara MJ; Jorge Vidal V; Mira Sirvent MC
    Farm Hosp; 2008; 32(5):280-5. PubMed ID: 19150043
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Inhibitors for the immuno- and constitutive proteasome: current and future trends in drug development.
    Huber EM; Groll M
    Angew Chem Int Ed Engl; 2012 Aug; 51(35):8708-20. PubMed ID: 22711561
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Speedy approvals for new cancer treatments.
    FDA Consum; 2003; 37(4):36. PubMed ID: 12971348
    [No Abstract]   [Full Text] [Related]  

  • 79. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy.
    Kane RC; Bross PF; Farrell AT; Pazdur R
    Oncologist; 2003; 8(6):508-13. PubMed ID: 14657528
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Focusing on boron in medicinal chemistry.
    Ramachandran PV
    Future Med Chem; 2013 Apr; 5(6):611-2. PubMed ID: 23617421
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.